Pharmacoepidemiology and Pharmacovigilance in the UK

A special issue of Pharmacoepidemiology (ISSN 2813-0618).

Deadline for manuscript submissions: 31 October 2025 | Viewed by 1049

Special Issue Editor


E-Mail Website
Guest Editor
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
Interests: public Health; pharmacoepidemiology; drug utilisation; health services research; statistical analyses; mixed-methods research; rational use of medicines

Special Issue Information

Dear Colleagues,

Medicines are the most common intervention in health care and account for a large share of health care spending. Although medicines undergo thorough testing before being approved for use, benefits to patients in routine practice may not be large as expected, and adverse events do occur, potentially resulting in patient harm. Furthermore, with ever-increasing prices for new medicines, the cost-effectiveness of pharmaceutical interventions may become debatable. In this context, pharmacoepidemiology and pharmacovigilance are important areas of research, providing insights into the use of medicines as well as their intended and unintended outcomes.

The UK has a long tradition of pharmacoepidemiology and pharmacovigilance; with a publicly funded system that provides universal health care, and electronic systems capturing a wide range of data, it is in a favourable position to conduct population-wide research in these areas. Considering developments such as an increasing population age, economic challenges, and public health threats such as the recent COVID-19 pandemic, obtaining an overview of current research and ongoing surveillance activities in the UK is warranted.

For this Special Issue, authors are invited to submit original research and comprehensive reviews on all aspects related to pharmacoepidemiology and pharmacovigilance in the UK. This may include (but is not restricted to) manuscripts focusing on methodological developments; clinically relevant findings; clinical and/or cost-effectiveness; and the relevance of research and its impact on clinical practice.

I look forward to receiving your contributions.

Dr. Tanja Mueller
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacoepidemiology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacoepidemiology
  • drug utilisation
  • pharmacovigilance
  • drug safety
  • clinical effectiveness
  • harm and benefits
  • UK

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 704 KB  
Article
Suspected Adverse Drug Reactions Associated with Leukotriene Receptor Antagonists Versus First-Line Asthma Medications: A National Registry–Pharmacology Approach
by Mohammed Khan, Christine Hirsch and Alan M. Jones
Pharmacoepidemiology 2025, 4(3), 18; https://doi.org/10.3390/pharma4030018 - 19 Sep 2025
Viewed by 245
Abstract
Background/Objectives: The aim of this study was to determine the suspected adverse drug reaction (ADR) profile of leukotriene receptor antagonists (LTRAs; montelukast and zafirlukast) relative to first-line asthma medications such as short-acting beta agonists (SABAs; salbutamol) and inhaled corticosteroid (ICS; beclomethasone) in [...] Read more.
Background/Objectives: The aim of this study was to determine the suspected adverse drug reaction (ADR) profile of leukotriene receptor antagonists (LTRAs; montelukast and zafirlukast) relative to first-line asthma medications such as short-acting beta agonists (SABAs; salbutamol) and inhaled corticosteroid (ICS; beclomethasone) in the United Kingdom. to determine the chemical and pharmacological rationale for the suspected ADR signals. Methods: Properties of the asthma medications (pharmacokinetics and pharmacology) were datamined from the chemical database of bioactive molecules with drug-like properties, the European Molecular Biology Laboratory (ChEMBL). Suspected ADR profiles of the asthma medications were curated from the Medicines and Healthcare products Regulatory Authority (MHRA) Yellow Card interactive Drug Analysis Profiles (iDAP) and concatenated to the standardised prescribing levels (using Open Prescribing data) between 2018 and 2023. Results: Total ADRs per 100,000 Rx (p < 0.001) and psychiatric system organ class (SOC) ADRs (p < 0.001) reached statistical significance. Montelukast exhibited the greatest ADR rate at 15.64 per 100,000 Rx. Conclusions: Relative to the controls, montelukast displays a range of suspected system organ class level ADRs. For the credible and previously reported psychiatric ADRs, montelukast is statistically significant (p < 0.001). A mechanistic hypothesis is proposed based on polypharmacological interactions in combination with cerebrospinal fluid (CSF) levels attained. Montelukast had the highest nervous disorder ADR rate at 1.71 per 100,000 Rx, whereas beclomethasone and salbutamol had lower rates (0.43 and 0.14, respectively). These ADRs share a similar background to psychiatric ADRs with CSF penetrability involved and affecting the dopamine axis. This work further supports the monitoring of montelukast for rare but important neuropsychiatric side effects. Full article
(This article belongs to the Special Issue Pharmacoepidemiology and Pharmacovigilance in the UK)
Show Figures

Figure 1

Back to TopTop